Top Clinical Trials companies in Taiwan by Debt to Equity Ratio
Taiwan
# |
Name |
Debt to Equity Ratio |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
0.51
|
Dec. 31, 2023 | USD 1.58 | NA |
|
Taiwan |
|
| 2 |
0.29
|
Dec. 31, 2023 | USD 2.60 | NA |
|
Taiwan |
|
| 3 |
0.13
|
Dec. 31, 2023 | USD 1.81 | NA |
|
Taiwan |
|
| 4 |
0.07
|
Dec. 31, 2023 | USD 0.34 | NA |
|
Taiwan |
|
| 5 |
0.05
|
Dec. 31, 2023 | USD 0.97 | NA |
|
Taiwan |
|
| 6 |
0.03
|
Dec. 31, 2023 | USD 2.34 | NA |
|
Taiwan |
|
| 7 |
0.00
|
Dec. 31, 2023 | USD 3.03 | NA |
|
Taiwan |
Frequently Asked Questions
-
Which Clinical Trials company in Taiwan has the highest Debt to Equity Ratio ?
The Clinical Trials company in Taiwan with the highest Debt to Equity Ratio is Medigen Vaccine Biologics Corporation (Taipei Exchange: 6547.TWO) at 0.51.
-
Which Clinical Trials company in Taiwan has the lowest Debt to Equity Ratio ?
The Clinical Trials company in Taiwan with the lowest Debt to Equity Ratio is PharmaEngine, Inc. (Taipei Exchange: 4162.TWO) at 0.00.
-
What are the top 10 Clinical Trials companies in Taiwan by Debt to Equity Ratio ?
The top 10 Clinical Trials companies in Taiwan by Debt to Equity Ratio are Medigen Vaccine Biologics Corporation, TaiMed Biologics Inc., OBI Pharma, Inc., TaiGen Biopharmaceuticals Holdings Limited, Microbio Co., Ltd., Oneness Biotech Co., Ltd. and PharmaEngine, Inc..
-
What are the bottom 10 Clinical Trials companies in Taiwan by Debt to Equity Ratio ?
The bottom 10 Clinical Trials companies in Taiwan by Debt to Equity Ratio are PharmaEngine, Inc., Oneness Biotech Co., Ltd., Microbio Co., Ltd., TaiGen Biopharmaceuticals Holdings Limited, OBI Pharma, Inc., TaiMed Biologics Inc. and Medigen Vaccine Biologics Corporation.
